Helix BioPharma (TSX:HBP) Change In Inventory : C$0.00 Mil (TTM As of Jan. 2025)

View and export this data going back to 1996. Start your Free Trial

What is Helix BioPharma Change In Inventory?

Helix BioPharma's change in inventory for the quarter that ended in Jan. 2025 was C$0.00 Mil. It means Helix BioPharma's inventory stayed the same from Oct. 2024 to Jan. 2025 .

Helix BioPharma's change in inventory for the fiscal year that ended in Jul. 2024 was C$0.00 Mil. It means Helix BioPharma's inventory stayed the same from Jul. 2023 to Jul. 2024 .

Helix BioPharma's Total Inventories for the quarter that ended in Jan. 2025 was C$0.00 Mil.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Inventory Turnover measures how fast the company turns over its inventory within a year.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Helix BioPharma Change In Inventory Historical Data

The historical data trend for Helix BioPharma's Change In Inventory can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Helix BioPharma Change In Inventory Chart

Helix BioPharma Annual Data

Trend

Jul15

Jul16

Jul17

Jul18

Jul19

Jul20

Jul21

Jul22

Jul23

Jul24

Change In Inventory

Get a 7-Day Free Trial

Helix BioPharma Quarterly Data
	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24	Apr24	Jul24	Oct24	Jan25
Change In Inventory	Get a 7-Day Free Trial															-	-	-	-	-

Helix BioPharma Change In Inventory Calculation

Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.

Change In Inventory for the trailing twelve months (TTM) ended in Jan. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was C$0.00 Mil.

Helix BioPharma (TSX:HBP) Change In Inventory Explanation

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Helix BioPharma's Days Inventory for the quarter that ended in is calculated as:

Days Inventory	=	Average Total Inventories	/	Cost of Goods Sold	*	Days in Period
	=	0	/	0	*	365 / 4
	=	N/A

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

Helix BioPharma's Inventory Turnover for the quarter that ended in Jan. 2025 is calculated as

Inventory Turnover	=	Cost of Goods Sold	/	Average Total Inventories
	=	0	/	0
	=	N/A

3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Helix BioPharma's Inventory to Revenue for the quarter that ended in Jan. 2025 is calculated as

Inventory-to-Revenue	=	Average Total Inventories	/	Revenue
	=	0	/	0
	=	N/A

Helix BioPharma Change In Inventory Related Terms

Thank you for viewing the detailed overview of Helix BioPharma's Change In Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.

Helix BioPharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Helix BioPharma Corp (TSX:HBP) » Definitions » Change In Inventory

Comparable Companies

Traded in Other Exchanges

HBP0:Germany

Address

40 Temperance Street, Suite 2700, Bay Adelaide Centre - North Tower, Toronto, ON, CAN, M5H0B4

Website

https://www.helixbiopharma.com

Helix BioPharma Corp is a clinical-stage biopharmaceutical company. It is focused on cancer drug development. The company develops therapies in the field of immuno-oncology based on its proprietary technology mainly in the areas of cancer prevention and treatment. Its pipeline candidate is L-DOS47 for Tumor Defence Breaker is in clinical trials for pancreatic cancer.